PDCD1 and lung adenocarcinoma: Notably, HDAC inhibition using pharmacological agents increased the levels of T cell chemoattractants and tumor infiltration into multiple lung adenocarcinomas, with a correlated sensitization to anti–programmed cell death protein 1 (anti–PD-1) therapy.